Skip to main content
. 2023 Oct 17;6:0252. doi: 10.34133/research.0252

Fig. 1.

Fig. 1.

AZGP1P2 is expressed at lower levels in CRPC cells and PCSC-like cells. (A) The enrichment of prostate cancer stem (PCSC)-like cells derived from PC3 cells via serum-free suspension culture. The sphere with a diameter of more than 100 μm was regarded as stem-like cells. Scale bars in A = 100 μm. (B) Western blots revealed the protein expression of stem cell markers, including CD133, CD44, KLF4, and SOX2, in PC3 and PC3-CSCs. (C) The relative expression of CD133, CD44, KLF4, and SOX2 in PC3 cells and PC3-CSCs after normalization to the signals of their loading control GAPDH. (D to F) Flow cytometry analysis showed the ALDH expression level in PC3 (D) and PC3-CSCs (E). (G) Real-time PCR showed the expression of AZGP1P2 mRNA in PC3, PC3-CSCs, DU145, and DU145-CSCs. (H) The correlation of AZGP1P2 expression and progression-free interval of 92 CRPC patients from the TCGA database. (I) Real-time PCR evaluated the expression of AZGP1P2 in PC3, DU145, 22RV1, Lncap, and RWPE-1 cell lines. (J) FISH assay showed the subcellular localization of AZGP1P2 in PC3 and DU145 cells. Scale bars in J = 10 μm. All the results were presented from 3 independent experiments. * denoted statistically significant differences (p < 0.05).